New HPV Blood Test May Transform Post-Surgery Treatment for Head and Neck Cancer Patients, Study Finds

The findings, published in Science Translational Medicine, suggest that the test could significantly improve post-surgical cancer management by providing a more precise assessment of residual disease and reducing the risk of both overtreatment and undertreatment.

According to senior author Daniel Faden, MD, Director of the Head and Neck Cancer Genomics and Liquid Biopsy Program at Mass General Brigham Cancer Institute, current treatment decisions following surgery for HPV-associated head and neck cancer are largely based on broad clinical risk factors. As a result, some patients receive more treatment than necessary, leading to additional side effects, while others may receive insufficient treatment and face a higher risk of cancer recurrence.

HPV-associated head and neck cancers develop when the human papillomavirus inserts its DNA into a person's cells, driving abnormal growth that leads to tumor formation. As tumor cells grow and die, they release tiny fragments of HPV DNA into the bloodstream. HPV-DeepSeek is designed to detect these minute fragments of viral DNA through a blood sample.

Earlier research conducted by the same team demonstrated that HPV-DeepSeek could detect HPV-associated head and neck cancers at the time of diagnosis with substantially higher accuracy than existing testing methods. Researchers also found evidence that the test may eventually serve as a screening tool capable of identifying cancers years before symptoms appear.

The latest investigation, known as the Clear-HPVca study, evaluated whether HPV-DeepSeek could be used to personalize treatment strategies after surgery. Researchers followed 103 patients with newly diagnosed, untreated HPV-associated head and neck cancer who were scheduled to undergo surgery at Mass General Brigham Cancer Institute between August 2020 and March 2024.

During the study, investigators collected and analyzed 560 blood samples obtained before surgery, after surgery, and during long-term surveillance. Participants were monitored for more than two years. Among the patients enrolled, 73 percent received additional treatment after surgery, including radiation therapy or chemoradiation.

At the time of diagnosis, HPV-DeepSeek detected circulating tumor HPV DNA in 98.1 percent of patients. During the critical post-surgical testing period, 23 percent of patients continued to show detectable levels of circulating tumor HPV DNA. Researchers reported that HPV-DeepSeek was substantially more sensitive than an existing HPV blood test.

The study revealed a striking difference in outcomes between patients with positive and negative HPV-DeepSeek results following surgery. Among patients with detectable tumor HPV DNA after surgery, only 60 percent remained disease-free after two years. In contrast, 100 percent of patients with negative test results remained disease-free during the same period.

Survival outcomes also differed significantly. Overall, 73 percent of patients with detectable tumor HPV DNA were still alive at the end of the study, compared with 98 percent of patients whose HPV-DeepSeek tests were negative after surgery.

Researchers further found that HPV-DeepSeek could identify cancer recurrence much earlier than traditional monitoring methods and currently available HPV DNA-based blood tests. The test detected recurrence approximately seven months before clinical diagnosis, nearly doubling the lead time offered by existing HPV DNA blood tests and, in some cases, identifying recurrence up to 17.5 months before conventional detection.

Despite the promising findings, researchers acknowledged several limitations. The study was observational, meaning investigators collected and analyzed data without using the test results to guide treatment decisions. The research was also conducted within a single healthcare system and included a relatively small number of patients whose cancer returned or who died during the study period.

Building on these results, the research team is preparing larger, multi-center clinical trials to evaluate whether HPV-DeepSeek can be used to guide treatment decisions after surgery for patients with HPV-associated head and neck cancer.

The study marks a significant step toward precision cancer care, offering the potential to identify patients at the highest risk of recurrence, improve survival outcomes, and tailor post-surgical treatment strategies with greater accuracy than existing approaches.